2009 update in prevention, evaluation, and outpatient treatment of influenza

Williams, James M.

doi:10.1185/03007990802708244

Cited by 9 publications

(4 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there are three separate clinical entities of BO. e severe injury to the lower respiratory tract can be caused by either a pathogen such as adenovirus, influenza, measles, respiratory syncytial virus, and mycoplasma pneumonia (PIBO) or lung, heart (LT-BO), or bone marrow transplantation (HSCT-BO) [3,7]. In addition, some cases of BO were triggered by toxic gases [8], chronic aspiration [9], connective tissue diseases [10], and certain drugs [11].…”

Section: Etiologymentioning

confidence: 99%

Postinfectious Bronchiolitis Obliterans in Children: Diagnostic Workup and Therapeutic Options: A Workshop Report

Jerkic

Brinkmann

Calder

et al. 2020

Canadian Respiratory Journal

View full text Add to dashboard Cite

Bronchiolitis obliterans (BO) is a rare, chronic form of obstructive lung disease, often initiated with injury of the bronchiolar epithelium followed by an inflammatory response and progressive fibrosis of small airways resulting in nonuniform luminal obliteration or narrowing. The term BO comprises a group of diseases with different underlying etiologies, courses, and characteristics. Among the better recognized inciting stimuli leading to BO are airway pathogens such as adenovirus and mycoplasma, which, in a small percentage of infected children, will result in progressive fixed airflow obstruction, an entity referred to as postinfectious bronchiolitis obliterans (PIBO). The present knowledge on BO in general is reasonably well developed, in part because of the relatively high incidence in patients who have undergone lung transplantation or bone marrow transplant recipients who have had graft-versus-host disease in the posttransplant period. The cellular and molecular pathways involved in PIBO, while assumed to be similar, have not been adequately elucidated. Since 2016, an international consortium of experts with an interest in PIBO assembles on a regular basis in Geisenheim, Germany, to discuss key areas in PIBO which include diagnostic workup, treatment strategies, and research fields.

show abstract

Section: Etiologymentioning

confidence: 99%

Postinfectious Bronchiolitis Obliterans in Children: Diagnostic Workup and Therapeutic Options: A Workshop Report

Jerkic

Brinkmann

Calder

et al. 2020

Canadian Respiratory Journal

View full text Add to dashboard Cite

show abstract

“…Treatment of viral pathogens, such as influenza, may shorten the duration of illness in low-risk patients but has not been shown to reduce the duration of illness in the high-risk population. 97 Treatment with ribavirin or intravenous immune globulin (IVIG) remain controversial in the setting of viral respiratory disease and are only used in select populations with severe RSV and human parainfluenza virus (HPIV) disease. 98,99 The relative ineffectiveness of antiviral compounds is, in part, because host inflammatory reaction leads to a substantial amount of pathology.…”

Section: Therapymentioning

confidence: 99%

The Human Bocaviruses: A Review and Discussion of Their Role in Infection

Chow

Esper

2009

Clinics in Laboratory Medicine

View full text Add to dashboard Cite

Respiratory tract infections are a leading cause of morbidity and mortality worldwide. The human bocavirus (HBoV) is a newly recognized human parvovirus first reported in 2005. Since its discovery, this virus has been associated with upper and lower respiratory tract disease and gastroenteritis worldwide. This article is a comprehensive review of what is known about HBoV. It includes an evaluation of diagnostic modalities, symptoms occurring in affected patients, and a discussion as to whether HBoV is responsible for identified clinical manifestations. The article reviews the incidence and effect of coinfection and updates on related members (HBoV-2 and HBoV-3) recently reported. Understanding of respiratory viruses such as HBoV remains vitally important to the health of adult and pediatric patients.

show abstract

“…Treatment of acute respiratory viral infections is difficult and results of interventional studies have not yet been convincing [1,9]. Management of influenza infections has shown especially that vaccination is much more effective than treatment of acute infection [10]. To date, we do not have an approved treatment for HRV infections and, given our experience with influenza, vaccination seems a much more sensible option.…”

mentioning

confidence: 99%